Abivax shares jump after strong trial results on drug obefazimod
Brief: Abivax Announces Acceptance Of Phase 3 Induction Trials
Brief: Abivax Announces Presentation Of Late-Breaking Abstract For Obefazimod From Abtect Phase 3 Induction Trials At 2025 UEG Meeting
French and Benelux stocks-Factors to watch
Brief: Euronext: Quarterly Review Of CAC Family
Brief: Abivax Posts H1 Operating Loss Of EUR 93.7 Mln
Brief: Abivax Announces Pricing Of $650 Mln Public Offering Of American Depositary Shares
Brief: Abivax Temporary Trading Halt Of Its Ordinary Shares On Euronext Paris
Brief: Abivax SA Files For Offering Of Up To $400 Mln Of American Depositary Shares - SEC Filing
Brief: Abivax Announces Launch Of Public Offering
Abivax hits record high after inflammatory bowel disease drug trial data
Abivax SA expected to post a loss of 73 cents a share - Earnings Preview
Abivax SA expected to post a loss of 68 cents a share - Earnings Preview
Brief: Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress
Abivax stock jumps after clinical trial milestone
French and Benelux stocks-Factors to watch
Brief: Abivax Achieves Key Milestone In Phase 3 Abtect Trial Enrollment
Brief: Abivax Announces A Change To The Composition Of Its Board Of Directors
Brief: Abivax SA Files For Mixed Shelf Of Up To $350 Million - SEC Filing